Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ester doai
Reexamination Certificate
2006-11-28
2006-11-28
Saucier, Sandra E. (Department: 1651)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ester doai
C424S078040
Reexamination Certificate
active
07141607
ABSTRACT:
Methods and compositions for the prophylactic and therapeutic treatment of retinal disorders associated with neovascularization using topical ophthalmic compositions comprising hydroxamic acid matrix metalloproteinase inhibitors such as batimastat.
REFERENCES:
patent: 2798053 (1957-07-01), Brown
patent: 4136250 (1979-01-01), Mueller et al.
patent: 4192827 (1980-03-01), Mueller et al.
patent: 4548990 (1985-10-01), Mueller et al.
patent: 4816456 (1989-03-01), Summers
patent: 5188826 (1993-02-01), Chandrasekaran et al.
patent: 5192535 (1993-03-01), Davis et al.
patent: 5240958 (1993-08-01), Campion et al.
patent: 5260059 (1993-11-01), Acott et al.
patent: 5332582 (1994-07-01), Babcock et al.
patent: 5340572 (1994-08-01), Patel et al.
patent: 5538721 (1996-07-01), Babcock et al.
patent: 5684152 (1997-11-01), Ponpipom et al.
patent: 5691382 (1997-11-01), Crimmin et al.
patent: 5696082 (1997-12-01), Crimmin et al.
patent: 5700838 (1997-12-01), Dickens et al.
patent: 5763621 (1998-06-01), Beckett et al.
patent: 5767153 (1998-06-01), Bowman et al.
patent: 5801156 (1998-09-01), Robinson et al.
patent: 5827702 (1998-10-01), Cuthbertson
patent: 5861436 (1999-01-01), Beckett et al.
patent: 5861510 (1999-01-01), Piscopio et al.
patent: 5863949 (1999-01-01), Robinson et al.
patent: 5866717 (1999-02-01), Beckett et al.
patent: 5872152 (1999-02-01), Brown et al.
patent: 5876744 (1999-03-01), Della Valle et al.
patent: 5902791 (1999-05-01), Beckett et al.
patent: 5917090 (1999-06-01), Huxley et al.
patent: 5925637 (1999-07-01), VanZandt et al.
patent: 5929097 (1999-07-01), Levin et al.
patent: 5932572 (1999-08-01), Dean et al.
patent: 5932695 (1999-08-01), Floyd et al.
patent: 6017949 (2000-01-01), D'Amato et al.
patent: 6239113 (2001-05-01), Dawson et al.
patent: 6375963 (2002-04-01), Repka et al.
patent: 6378526 (2002-04-01), Bowman et al.
patent: 6455283 (2002-09-01), Ferrara et al.
patent: 2002/0032315 (2002-03-01), Baca et al.
patent: 0312208 (1988-09-01), None
patent: 0 895 988 (1999-02-01), None
patent: 0 930 067 (1999-07-01), None
patent: 1040837 (2000-10-01), None
patent: WO 9529696 (1995-11-01), None
patent: WO 9603985 (1996-02-01), None
patent: WO 97/18835 (1997-05-01), None
patent: WO 97/43245 (1997-11-01), None
patent: WO 97/43247 (1997-11-01), None
patent: WO 9741844 (1997-11-01), None
patent: WO 98/07697 (1998-02-01), None
patent: WO 98/09940 (1998-03-01), None
patent: WO 98/12211 (1998-03-01), None
patent: WO 9810758 (1998-03-01), None
patent: WO 98/16520 (1998-04-01), None
patent: WO 98/33768 (1998-08-01), None
patent: WO 9913909 (1999-03-01), None
patent: WO 99/19296 (1999-04-01), None
patent: WO99/22713 (1999-05-01), None
patent: WO 9945929 (1999-09-01), None
patent: WO-9958126 (1999-11-01), None
patent: WO-007565 (2000-02-01), None
patent: WO 0007565 (2000-02-01), None
patent: WO 0007565 (2000-02-01), None
patent: WO 00/40089 (2000-07-01), None
Ricci et al., “Oxygen-induced retinopathy in the newborn rat: effects of hyperbarism and topical administration of timolol maleate”, Graefe's Archive for Clinical and Experimental Ophthalmology 233 (4) : 226-30 (1995).
MedlinePlus Medical Dictionary definition of pterygium.
MedlinePlus Medical Dictionary definition of prophylaxis.
ARVO Abstract Book, Annual Meeting Fort Lauderdale, Florida May 9-14, 1999, IOVS, Mar. 1999, vol. 40, No. 4, p. S231.
Arup Das, et al.,Human Diabetic Neovascular Membranes Contain High Levels of Urokinase and Metalloprotinase Enzymes, IOVS, Mar. 1999, vol. 40, No. 3, 809-813.
Arup Das, et al.,Retinal Neovascularization Is Suppressed With a Matrix Metalloproteinase Inhibitor, Archive of Ophthalmology, vol. 117, No. 4, Apr. 1999, 498-503.
Joseph Frucht-Pery, MD, et al.,Topical Indomethacin Solution Versus Dexamethasone Solution for Treatment of Inflamed Pterygium and Pinguecula: A Prospective Randomized Clinical Study, American Journal of Ophthalmology, Feb. 1999, vol. 127, 148-152.
G. A. Lutty, et al.,Nonperfusion of retina and choroid in transgenic mouse models of sickle cell disease, Current Eye Research, vol. 17, No. 4, Apr. 1998, 438-444.
N. N. Osborne, et al.,Topically Applied Betaxolol Attenuates NMDA-induced Toxicity to Ganglion Cells and the Effects of Ischaemia to the Retina, Exp. Eye Res. (1999) 69, 331-342.
Gholam A. Peyman,Vitreoretinal Diseases: Pathological Aspects and Therapeutic Strategies, Ocular Therapeutics and Drug Delivery A Multi-Disciplinary Approach, 265-266.
Lutz E. Pillunat, et al.,Effect of topical dorzolamide on optic nerve head blood flow, Craefes Arch Clin Exp Ophthalmol (1999) 237: 495-500.
Maria Emanuel Ryan, et al.,MMP-Mediated Events in Diabetes, Annals of the New York Academy of Sciences Vol. 878 Inhibition of Matrix Metalloproteinases Therapeutic Applications, 1999, 311-334.
Sebastian Wolf, et al.,Acute effect of metipranolol on the retinal circulation, British Journal of Ophthalmology 1998; 82: 892-896.
Edward J. Zabawski, Jr., Do, et al.,Topical and intralesional cidofovir: A review of pharmacology and therapeutic effects, Journal of the American Academy of Dermatology1998; 39: 741-5.
Baraldi, et al.,Synthesis, in Vitro Antiproliferative Activity, and DNA-Binding Properties of Hybrid Molecules Containing Pyrrola[2.1-c][1.4]b benzodiazepine and Minor-Groove-Binding Oligopyrrole Carriers, Journal of Medical Chemistry 42(25): 5131-41 (1999).
Bayless, et al.,RGD-Dependent Vacuolation and Lumen Formation Observed during Endothelial Cell Morphogenesis in Three-Dimensional Fibrin Matrices Involves the avB3and a5B1Integrins, American Journal of Pathology 156(5): 1673-83 (2000).
Bevilacqua, et al.,Recent Contributions to Knowledge of the Mechanism of Action of Nimesulide, Drugs 46 Suppl. 1: 40-47 (1993).
Bigg, et al.,Mechanisms of induction of human tissue inhibitor of metalloproteinases-1(TIMP-1)gene expression by all-trans retinoic acid in combination with basic fibroblast growth factor, European Journal of Biochemistry 267(13): 4150-56 (2000).
Binetruy-Tournaire, et al.,Identification of a peptide blocking vascular endothelial growth factor(VEGF)-mediated angiogenesis, EMBO J. 19(7): 1525-33 (2000).
Campbell, et al.,Malonyl aa-Mercaptoketones and a-Mercaptoalcohols, A New Class of Matrix Metalloproteinase Inhibitors, Bioorganic Medical Chemistry Letters 8(10): 1157-62 (1998).
Cherney, et al.,Macrocyclic Hydrozamate Inhibitors of Matrix Metalloproteinases and TNF-a Production, Bioorganic Medical Chemistry Letters 9(9): 1279-84 (1999).
Colombo, S., et al., “An Eye Drop Form of an Extracellular Proteinase Inhibitor Prevents Retinal Neovascularization in an Animal Model,” Biosciences Information Service cited as XP002183948 on the International Search Report dated Mar. 15, 2000.
Colorado, et al., Anti-angiogenic Cures From Vascular Basement Membrane Collagen, Cancer Research 69(9): 2520-26 (2000).
Coors, et al., The Investigative Ophthalmology & Visual Sciences 40(4): S231 (1999).
Dark, et al.,Combretastatin A-4, an Agent that Displays Patent and Selective Toxicity toward Tumor Vasculature, Cancer Research 57 (10): 1829-34 (1997).
Fairbrother, et al.,Novel Peptides Selected to Bind Vascular Endothelial Growth Factor Target the Receptor-Binding Site, Biochemistry 37(51): 17754-64 (1998).
Fife, et al., Effects of tetracyclines on angiogenesis in vitro, Cancer Letters: 153(1-2): 75-8 (2000).
Fini, et al.,An Inhibitor of the Matrix Metalloproteinase Synthesized, Invest. Ophthalmol. Vis. Sci. 32(11): 2997-3001 (1991).
Floege, et al.,Novel Approach to Specific Growth Factor Inhibition in Vivo, American Journal of Pathology 154(1): 169-79 (1999).
Gilbertson-Beadling, et al.,The tetracycline analogs minocycline and doxycycline inhibit angiogenesis in vitro by a non-metalloproteinase-dependent mechanism, Cancer Chemother, Pharmacol. 36(5): 418-24 (1995).
Greenwald, et al.,Tetracyclines Suppress Matrix Metalloproteinase Activity in Adjuvant Arthritis and in Combination with Flurbiprofen, Ameliorate Bone Damage, Journal of Rheumatology 19(6): 927-38 (1992).
Griscelli, et al.,Angiostatin gene transfer: Inhibition of tumor growth in vivo by blockage of endothe
Bowman Lyle M.
Si Erwin
Insite Vision Incorporated
McDermott Will & Emery LLP
Saucier Sandra E.
LandOfFree
Methods and compositions for treating and inhibiting retinal... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for treating and inhibiting retinal..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for treating and inhibiting retinal... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3632562